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among treatments. Hemodynamic effects were comparable be-Dialysate calcium profiling during hemodialysis: Use and clini-
tween LdCa and MdCa treatments. Intradialytic events werecal implications.
reduced (P  0.05) only with the dCaP treatment.Background. Low dialysate calcium (LdCa) concentration
Conclusions. The drop in BP observed during the last twois used to prevent or treat hemodialysis (HD)-induced hyper-
hours of HD in both the LdCa and MdCa groups was abolishedcalcemia, but its use has been complicated by intradialytic hypo-
in the dCaP group. The latter was accomplished via an increasetension in some patients. Our goal was to explore the possibility
in cardiac output, due to an iCa-induced increase in myocardialthat dialysis calcium profiling (dCaP) can ameliorate intradia-
contractility. Therefore, dCaP, by individualizing the dCa con-lytic hypotension in HD patients who need to have dialysis
centrations used and timing the switching between them, mayperformed with LdCa.
improve intradialytic BP instability and simultaneously mini-Methods. In a randomized crossover design, eighteen HD
patients underwent one four-hour HD session with LdCa of mize the risk for HD patients to develop hypercalcemia.
1.25 mmol/L (LdCa group) and one four-hour HD session with
LdCa of 1.25 mmol/L during the first two hours and high dCa
of 1.75 mmol/L during the remaining two hours (dCaP group).
Symptomatic or asymptomatic hypercalcemia is a veryAfter that, they underwent another four-hour HD session with
common problem encountered in hemodialysis (HD) pa-medium dCa of 1.5 mmol/L (MdCa group). Before HD and
at four 60-minute intervals during the HD sessions, blood pres- tients [1–4]. This HD-induced hypercalcemia is mainly
sure (BP), heart rate (HR) and noninvasive measurements of due to the positive intradialytic calcium balance achieved
cardiac index (CI), using bioelectrical impedance, were ob- with the use of a standard dialysate calcium (dCa) con-tained. Ionized serum calcium (iCa) also was measured before
centration of 1.75 mmol/L [5] and the administrationHD and at 120 and 240 minutes into the HD session. In a
of calcium-containing phosphate binders in conjunctionseparate study, eight HD patients were treated for three weeks
with 1.25 mmol/L dCa and three weeks with the dCaP tech- with active vitamin D metabolites for the treatment of
nique described above, in random order. A three-week treat- secondary hyperparathyroidism. To minimize the inci-
ment with MdCa followed. BP and symptoms were recorded dence and the degree of hypercalcemia in such patients,during each HD session.
the use of lower dialysate calcium concentrations (LdCa)Results. During the LdCa treatment the iCa values remained
has been proposed [3–8].unchanged, whereas mean arterial pressure (MAP) and CI
decreased by 16.5  8.3% and 14.2  14.6%, respectively, at However, a number of recent investigations showed that
the end of HD. During the first half of the dCaP treatment, a significant decrease of blood pressure (BP) occurs during
iCa, MAP and CI decreased by 2.2  4.1%, 12.6  12.3%, HD with 1.25 mmol/L dCa as compared to 1.75 mmol/Land 9.6  13.4%, respectively, whereas during the second half
dCa in both healthy [9, 10] and cardiac-compromisedof the same treatment, iCa, MAP and CI values increased by
HD patients [11]. Conversely, an intradialytic increase of10.2  3.3%, 7.8  7.2% and 10.8  9.1%, respectively, from
the middle HD values. ANOVA showed that the time treat- serum calcium level, which occurs with the use of high
ment effect was significant for iCa, MAP and CI. Total periph- dCa concentrations, has been consistently shown to im-
eral resistance and HR changes were insignificant and similar prove left ventricular performance during HD [12–14],
and thus, increasing the dCa concentrations has been
advocated as a means of protection against intradialyticKey words: hypercalcemia, intradialytic blood pressure, hypotension,
hemodynamics, secondary hyperparathyroidism, end-stage renal disease. hypotension [11, 12].
With this background, it is evident that HD patientsReceived for publication November 21, 2000
who need a dCa of 1.25 mmol/L or less as a means toand in revised form July 24, 2001
Accepted for publication August 9, 2001 treat and/or prevent HD-related hypercalcemia have a
potential risk of developing intradialytic hypotension, 2002 by the International Society of Nephrology
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which is a significant cause of patient morbidity. In an underwent another four-hour HD treatment with a me-
dium dCa concentration of 1.5 mmol/L (MdCa group).attempt to overcome this problem, we developed a dialy-
sate calcium profiling (dCaP) technique and tested it in All patients were dialyzed on a Gambro AK dialysis
machine (Gambro, Lund, Sweden), with the ultrafiltrationthe present study. Specifically, we undertook this work
to answer the question of whether intradialytic hypoten- adjusted to achieve the individual’s estimated dry weight.
Hemophane hollow-fiber dialyzers (Gambro) were usedsion, seen mainly toward the end of HD with the use of
1.25 mmol/L dCa, can be abolished in the second half in all treatments. The composition of the dialysate was:
Na 140 mmol/L, K 2 mmol/L, Mg 0.5 mmol/L, bicarbon-of the HD session, by increasing the dCa concentration
from 1.25 to 1.75 mmol/L in the middle of the dialysis ate 35 mmol/L, acetate 3 mmol/L, Cl 109.5 mmol/L and
Ca 1.75 or 1.25 mmol/L. Blood flow was 250 mL/minsession. If a positive result could be obtained, then mod-
eling the dCa concentration may prove to be an impor- and dialysate flow was 500 mL/min. During each of the
three intervention treatments, the biochemical and he-tant tool to prevent HD-induced hypercalcemia without
jeopardizing hemodynamic stability during HD. modynamic parameters were measured as described in
the next sections.
METHODS Biochemical parameters
Study A Arterial blood samples were drawn before, in the mid-
dle (120 min) and at the end (240 min) of HD, for deter-Eighteen patients were studied, eight women and ten
men, 61  15 years old (range, 40 to 85 years) with a mination of ionized serum calcium (reference value 1.07
to 1.27 mmol/L), by the use of a Stat Profile 4 analyzermean time on intermittent hemodialysis therapy of 31 
24 months (range, 8 to 88 months). Inclusion criteria in (Nova Biomedical, Waltham, MA, USA).
this study were: no clinical history suggestive of ischemic
Hemodynamic parameterscardiac disease; no wall motion abnormalities and valve
heart disease present on echocardiographic examination; Each one of the following hemodynamic parameters
was measured before dialysis, and at one-hour intervalsuncompromised left systolic function (ejection fraction
40%); and normal sinus rhythm. The etiology of renal during the subsequent four-hour dialysis period. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP)failure was hypertensive nephrosclerosis (N  6), inter-
stitial nephritis (N  4), diabetic nephropathy (N  2), were measured with an automatic blood pressure device
(Datex-Ohmeda; Instrumentarium Corp., Helsinki, Fin-mesangiocapillary glomerulonephritis (N 1), polycystic
kidney disease (N  1), retroperitoneal fibrosis (N  land) and mean arterial pressure (MAP) was computed
as the DBP plus the 1/3 of the pulse pressure. The mean1), and undetermined (N  3). Thirteen patients were
normotensive (BP 140/90 mm Hg) within the last year, of three consecutive measurements was calculated. Car-
diac index (CI), the cardiac output (CO) indexed by bodywhereas five patients with mild systolic hypertension
(SBP  160 mm Hg) were asked to discontinue antihy- surface area, and heart rate (HR) were derived from tho-
racic electric bioimpedance (TEB) data obtained with thepertensive drugs one week before the study period. Be-
fore the study, 10 out of 18 patients were dialyzed with NCCOM3-R7/CDDP system (manufactured by Cardio-
Dynamics International Corp., Irvine, CA, USA). The1.75 mmol/L dCa and the remaining 8 patients were
dialyzed with 1.25 mmol/L dCa. All patients gave in- validity, limitations, and reproducibility of the TEB to
measure CO have been described by others [15–18]. Theformed consent to participate in the study, which had
been approved by the Institutional Board of General method was straightforward: electrodes were attached to
the patient’s neck and thoracic cavity along with an elec-Hospital of Chios.
trocardiogram (EKG) recording electrode. Then, the ap-
Study design paratus analyzed the impedance signals from the thoracic
cavity and aorta to determine the CO. Total peripheralAll patients, with each one serving as his or her own
control, underwent a single four-hour HD treatment with resistance index (TPRI) was calculated as TPRI  80 
MAP/CI, where 80 is a conversion factor.a low dCa concentration of 1.25 mmol/L (LdCa group)
and a single four-hour HD session with LdCa of 1.25
Study Bmmol/L during the first two hours and high dCa of
1.75 mmol/L during the remaining two hours (dCaP This short-term study evaluated the dCaP as a means
to optimize dialysis therapy. Eight normotensive HDgroup). The order of the two treatments was randomized.
The patients and the nursing staff were not aware of patients, four men and four women, with a mean age of
61.8  12.1 years (range, 44 to 84 years) were includedwhich treatment was taking place. Only the technician
of the dialysis department knew the concentration of in the study. Exclusion criteria were compromised left
ventricular function (ejection fraction 30% or less) andcalcium in the dialysate used for each treatment. After
the completion of these two dCa treatments, all patients diabetes mellitus. All patients had been maintained on
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1.25 mmol/L dCa for more than six months prior to the checked for the presence of period and carryover effects
during the crossover phase of the study. A two-treatmentstudy, after having been switched from a 1.75 mmol/L dCa
due to HD-related hypercalcemia (iCa  1.38 mmol/L). (LdCa vs. dCaP), two-period crossover analysis was per-
formed, after including the period and carryover terms inBone biopsy had not been performed on any patient.
Based on the parathyroid hormone (PTH) serum levels, the analysis of variance model. No period and carryover
effects (all P  0.760) were detected for any variablefive out of these eight patients were suffering from oste-
itis fibrosa (PTH  400 pg/mL) and were treated with measured. Results were similar with and without car-
ryover in the model. The possible roles, if any, of agecalcitriol and CaCO3 supplements, while the remaining
three patients had presumably adynamic bone disease and gender in the observed iCa-induced hemodynamic
changes as well as the possibility of an interaction be-(PTH 70 pg/mL) and were using CaCO3 to treat hyper-
phosphatemia. Each patient was dialyzed, in randomized tween these factors and treatment were assessed with
analysis of covariance (ANCOVA).order, for three weeks with a low dCa of 1.25 mmol/L
(LdCa group) and another three weeks with the dCaP In analyzing iCa and the blood pressure data from
study B, a two-factor repeated measures ANOVA designtechnique (dCaP group), as described above. After the
completion of these two three-week HD treatments, all was used as above, except that iCa and the blood pressure
values from three and nine sessions, respectively, werepatients underwent another three-week treatment with
a medium dialysate calcium concentration of 1.5 mmol/L averaged first at each time point prior to analysis. Data
were pretested for period and carryover effects during(MdCa group). Blood pressure and heart rate were mea-
sured before dialysis and every hour during dialysis, and the crossover phase of the study as described in study A.
Again, there was no evidence of a period or carryover ef-intra-session events were recorded in each treatment.
The latter included symptomatic or asymptomatic hypo- fect (all P  0.611) of any treatment on iCa, blood pres-
sure and heart rate measurements. For analysis of thetension and episodes of muscle cramping, headache and
lightheadedness (referred together as dialysis intoler- symptoms, each dialysis session was scored as zero or 1
for each symptom. Cochran’s Q statistic was used to testance). Symptomatic hypotension was defined as the re-
quirement of volume expansion therapy due to either a for differences in symptoms between treatments. For
two group comparisons, the McNemar test was useddecrease in SBP of more than 40 mm Hg below the pre-
dialysis SBP, a decrease in SBP below 95 mm Hg, or a instead. Parameters are expressed as absolute values or
as percentage changes from baseline. Values are ex-decrease in blood pressure accompanied by symptoms
requiring intervention. Asymptomatic hypotension was pressed as mean SD, unless otherwise stated. Changes
were considered statistically significant for P less thandefined as a SBP of less than 95 mm Hg without symp-
toms. The time of occurrence of a hypotensive episode 0.05 (two-sided).
was considered to be early when it happened during the
first two hours of dialysis or late when it occurred there-
RESULTS
after. At 0, 120, 240 minutes during the second midweek
Study Adialysis session of each week, blood samples were drawn
for iCa measurement. The dialysis parameters in study Hemodynamic indices, ionized serum calcium (iCa)
and body weights were similar prior to the treatmentsB were the same as in study A. Doses of vitamin D and
CaCO3 were not modified and no changes of diet habits (Table 1). The mean ultrafiltration rate was 0.27  0.18
L/h, 0.29  0.21 L/h, and 0.29  0.17 L/h in the dCaP,were introduced during the entire study period.
LdCa and MdCa groups, respectively. In all of the treat-
Statistical analysis ments (N  18), hypotension necessitating the adminis-
tration of normal saline occurred in 22.2% (N  4) inStatistical analysis was performed using SPSS/PC 8.0
microcomputer statistical software package (SPSS Inc., both LdCa and MdCa groups and in 5.6% (N  1) in
the dCaP group. Both the ultrafiltration rate and theChicago, IL, USA). As there were multiple time points for
each of the three treatments, a two-factor (time  treat- number of hypotensive episodes were not statistically
different between treatment groups.ment) repeated measures analysis of variance (ANOVA)
design was used. If a treatment or a time  treatment Ionized serum Ca remained unchanged during HD in
the LdCa (from 1.16  0.09 to 1.14  0.07 mmol/L) andeffect was found, then the treatment effect at each time
point was further explored by first performing repeated MdCa (from 1.15  0.11 to 1.18  0.05 mmol/L) groups,
respectively (Fig. 1A). In contrast, in the dCaP group,measures ANOVA at that time point. If this analysis
yielded a significant treatment effect, then the three the use of 1.75 mmol/L dCa during the last two hours
of dialysis caused iCa to increase significantly (P 0.001)treatments were compared by performing the least sig-
nificant difference (LSD) pair-wise multiple comparison from a mean 1.13  0.08 in the middle of HD (mid-HD)
to 1.26  0.08 mmol/L at the end of the HD session.test. The significance of a time effect also was analyzed
within each treatment. Prior to this analysis, data were Mid-HD iCa in the MdCa group was higher by 0.04 
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Table 1. Baseline (predialysis) biochemical and hemodynamic data in the dialysate calcium profiling (dCaP) group, low (1.25 mmol/L)
dialysate calcium (LdCa) group and medium (1.5 mmol/L) dialysate calcium (MdCa) group
dCaP LdCa MdCa
Study A (N18)
Serum ionized calcium mmol/L 1.160.10 1.160.09 1.150.11
Body weight kg 64.810.6 64.710.6 6411.6
Systolic blood pressure mm Hg 131.512.3 130.621 132.913.7
Diastolic blood pressure mm Hg 69.610.6 70.211.8 72.810.5
Mean arterial pressure mm Hg 90.28.9 90.314.3 93.18.3
Cardiac index L/min/m2 3.61.2 3.41.2 3.31.1
Stroke index mL/m2 46.116.6 44.316.2 43.515.5
Heart rate bpm 78.511.1 77.910.2 79.514.4
Total peripheral resistance index dyn · sec/cm5/m2 2280940 2380943 2506962
Study B (N8)
Average of 3 sessions
Serum ionized calcium mmol/L 1.220.07 1.170.06 1.190.1
Average of 9 sessions
Body weight kg 68.412.4 68.912.9 68.612.9
Systolic blood pressure mm Hg 132.48.1 133.38.5 133.48.7
Diastolic blood pressure mm Hg 70.56.6 70.66.4 71.96.8
Mean arterial pressure mm Hg 91.15.6 91.56 92.55.8
Heart rate bpm 70.88 71.38.4 71.87.9
Data are expressed as mean  SD.
0.06 mmol/L (P  0.05) than that seen in both dCaP Total peripheral resistance index and HR were not
significantly altered during HD, and intradialytic changesand LdCa groups, whereas post-HD iCa in the dCaP
group was higher by 0.11  0.05 (P  0.001) and 0.08  did not significantly differ between treatments. Thus, the
blood pressure effect was primarily due to changes in0.08 mmol/L (P 0.001) than that seen in the LdCa and
MdCa groups, respectively. According to the two-factor cardiac output, through analogous changes in stroke vol-
ume. Changes in CI were parallel to those of MAP (Fig. 2).repeated measures ANOVA design used in this study,
both the treatment (P  0.05) and time  treatment During the first half of HD, the CI was reduced to the
same extent in the three treatment groups, decreasinginteraction (P  0.001) effects for iCa were statistically
significant. A time effect was present only with the dCaP by 9.6  13.4% (P  0.05), 7.3  13.4% (P  0.05) and
4.2  12.5% (P  0.05) in the dCaP, LdCa and MdCatreatment (P  0.001).
The hourly intradialytic percentage changes in blood groups, respectively. In the dCaP group, switching from
a 1.25 to 1.75 mmol/L dCa in the middle of HD not onlypressure are shown in Figure 2, and the pre- to mid-HD
and mid- to post-HD intra-group changes, as well as prevented the continuous fall of CI during the last two
hours of HD seen in both LdCa group (from 7.3 13.4%post-HD inter-group differences in blood pressure, are
depicted in Figure 3. During the first half of HD, MAP to 14.2  14.6%; P 0.05) and MdCa group (from 4.2
12.5% to 7.4  12.4; P  0.05), but also caused CI todropped to the same extent in the three treatment
groups. It decreased significantly by 12.6  12.3% (P  overshoot baseline levels by 2.9  10.8%. Thus, at the
end of HD, dCaP treatment had significantly prevented0.01), 10.6  9.8% (P  0.001) and 10.5  9.9 (P 
0.001) in the dCaP, LdCa and MdCa groups, respectively. the fall of CI observed with LdCa (P 0.001) and MdCa
(P  0.01) treatments. Figure 4 details the pre- to mid-During the second half of HD, MAP in the dCaP group,
as a result of the increase in iCa, rose progressively and HD and mid- to post-HD intra-group changes as well as
post-HD inter-group differences in CI. The treatmentreturned to baseline levels by the end of dialysis. On
the contrary, in the LdCa and MdCa groups, where iCa effect (P  0.05), time effect (P  0.05), and time 
treatment interaction effect for CI (P  0.001) wereremained unchanged throughout the dialysis period,
MAP continued to decrease, ending up with a fall of statistically significant. In addition, a time effect was seen
with both dCaP (P  0.001) and LdCa (P  0.001)16.5  8.3% (P  0.001) and 15.4  10% (P  0.001),
respectively, at the end of the dialysis session. The time treatments, but not with the MdCa treatment. The profile
of SI changes was similar to that of CI (Fig. 4). Thetreatment interaction (P  0.001) for MAP was statisti-
cally significant and, additionally, a time effect was seen treatment effect (P  0.05), time effect (P  0.01), and
time  treatment effect (P  0.01) for SI were statisti-with each of the three dCa treatments (P  0.001). The
intra-session changes of both SBP and DBP were analo- cally significant. A time effect was seen with both dCaP
(P 0.05) and LdCa (P 0.01) treatments, but not withgous to that of MAP (Figs. 2 and 3). There was a signifi-
cant time treatment effect (P 0.01) and a time effect the MdCa treatment. Finally, covariance analysis showed
that the iCa-induced hemodynamic changes during HD(P  0.001) for both SBP and DBP.
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Study B
Pre-dialysis values of the measured parameters are
presented in Table 1. Mean pre-HD iCa levels did not
differ among the treatment groups, and the iCa levels
remained unchanged during HD with the LdCa and
MdCa treatments, whereas during dCaP treatment it
decreased by 0.04  0.05 mmol/L (from 1.22  0.07 to
1.17  0.05 mmol/L; P  0.05) in the first two hours of
HD and, in turn, increased up to the level of 1.28 
0.08 mmol/L (P  0.01) by the end of HD (Fig. 1B).
The mid-HD iCa level did not differ among the treat-
ment groups, whereas the post-HD iCa in the dCaP
group was higher by 0.14  0.07 (P  0.001) and 0.08 
0.010 mmol/L (P 0.05) than that seen in the LdCa and
MdCa groups, respectively. The treatment effect (P 
0.05), the time  treatment effect (P  0.001), and the
time effect with the dCaP treatment (P  0.001) were
statistically significant.
Blood pressure differences between the three treat-
ments are shown in Figure 5. The pattern of BP changes
detected was quite similar to that observed in the hemo-
dynamic study. Again, blood pressure changes did not
differ between the LdCa and MdCa treatments, whereas
a beneficial effect on blood pressure was seen only with
the dCaP treatment. There was a treatment effect for
both DBP (P  0.05) and MAP (P  0.05) but not for
SBP. For SBP, DBP and MAP the time  treatment
effect (P  0.001) and the time effect (P  0.001) were
statistically significant. There were no significant differ-
ences in mean (3-week) pre-HD weight and fluid loss
between the three groups. The ultrafiltration rate was
0.470  0.18 L/h, 0.470  0.17 L/h and 0.462  0.16 L/hFig. 1. Changes in serum ionized calcium (iCa) during hemodialysis.
Symbols are: () dialysate calcium profiling (dCaP), () low (1.25 in the dCaP, LdCa and MdCa groups, respectively.
mmol/L) dialysate calcium (LdCa), () medium (1.5 mmol/L) dialysate However, ANOVA analysis of the hemodynamic data
calcium (MdCa); (*) a significant difference between dCaP group and
(9 measurements) performed on each patient individu-both LdCa and MdCa groups; (**) a significant difference between
MdCa and LdCa groups; () a significant difference between MdCa ally revealed that iCa rising in the middle of HD exerted a
group and both LdCa and dCaP groups. Data points represent mean significantly positive hemodynamic effect on five patientsvalues  SD.
(responders), whereas it did not impact significantly on
three patients (non-responders). Analysis of the individ-
ual time points suggested that MAP decreased over time
to a much greater extent (P  0.001 for the interaction)
were independent from age and gender, and no signifi- with the LdCa than with the dCaP treatment in the
cant interaction was found between these factors and responders group, whereas changes in MAP were similar
treatment. among treatments in the non-responders group (Fig. 6).
These findings indicated that (1) dCa concentration Interestingly, the fall of MAP averaged across time, ob-
was a major determinant of iCa during HD; (2) the served with LdCa treatment in the non-responders group,
changes in iCa correlated to both changes in BP and CI; was significantly (P  0.05) lower by 4.9  1.7% than
(3) the BP alterations observed during HD correlated it was in the responders group (6.7  1.6 vs. 11.6 
to parallel alterations in CI; (4) intradialytic changes of 2.5%). The LdCa intervention caused SBP and DBP to
calcemia did not impact significantly on TPR and HR; decrease by 22.9  7.2 and 17.9  4.9%, respectively,
(5) hemodynamic changes, for all measured parameters, at the end of HD in the responders group, whereas with
were comparable between LdCa and MdCa treatments; the same intervention, SBP and DBP decreased by 11 
and (6) the iCa-induced hemodynamic changes were 5.1 and 10.3 1.1%, respectively, in the non-responders
group. The difference for both SBP (12  4.8%) andconsistent across gender and age.
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Fig. 2. Hourly intradialytic percent changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and
cardiac index (CI). Symbols are: () dialysate calcium profiling (dCaP); () low (1.25 mmol/L) dialysate calcium (LdCa); () medium (1.5 mmol/L)
dialysate calcium (MdCa); (*) significant difference between dCaP group and both LdCa and MdCa groups. Data points represent mean values 
SEM. (Study A, N  18).
DBP (7.6  2.3%) between the two groups was statisti- nificant reduction in the late symptomatic hypotension
cally significant (P  0.05). These observations hint that (P  0.037) that was not observed with early symptom-
the greater the intensity of the 1.25 mmol/L Ca dialysate- atic hypotension. The same also was true for late total
induced intradialytic hypotension, the more favorable hypotension (P 0.014). No significant differences were
the hemodynamic response when the dCaP is applied. detected in any symptom between the LdCa and MdCa
Significant and borderline significant differences in in- treatments. These findings clearly demonstrated the ef-
tradialytic symptoms between the three treatment proto- ficiency of a high dCa concentration of 1.75 mmol/L, as
cols are illustrated in Table 2. There were fewer episodes the basic component of the dCaP technique, to amelio-
of total (symptomatic and asymptomatic) hypotension rate intradialytic morbidity for the last two-hour period
(P 0.040) and total intradialytic symptoms (P 0.026) of HD when it was used.
with the dCaP treatment compared with both LdCa and
MdCa treatments. There were no significant differences
DISCUSSIONin asymptomatic hypotension and dialysis intolerance
Our results indicate that dCa profiling during HDamong the three dCa treatments. Although there was
might prove to be an important therapeutic option inmuch less symptomatic hypotension with the dCaP treat-
treating HD-related hypercalcemia. It was found to bement, this difference did not reach statistical significance
superior to the standard 1.25 mmol/L dCa treatment with(P  0.12). However, when considering the time of oc-
currence of hypotension, dCaP treatment caused a sig- regard to dialysis tolerance, and it may exert (although
Fig. 3. Changes in systolic blood pressure
(SBP), diastolic blood pressure (DBP), and
mean arterial pressure (MAP) during hemodi-
alysis. Symbols are: () dialysate calcium pro-
filing (dCaP); () low (1.25 mmol/L) dialysate
calcium (LdCa); () medium (1.5 mmol/L) di-
alysate calcium (MdCa). The numbers above
horizontal arrows are the mean changes in
blood pressure during the first half (0 to 2
hours) and second half (2 to 4 hours) of a four-
hour HD session. Vertical arrows indicate the
mean differences in blood pressure between
the three treatment groups at the end of HD,
which are presented in the left lower part of
each graph. The corresponding mean differ-
ences in the middle of HD were not statisti-
cally significant and pertaining data are not
shown. The 95% level confidence interval for
the means is given in parentheses. Unidirec-
tional arrows are used for simplicity, although
the order in which participants were given the
dCa treatments was random with a crossover
design. *P  0.05, **P  0.01, ***P  0.001.
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Fig. 4. Changes in cardiac index (CI) and
stroke index (SI) during hemodialysis. Symbols
are: () dialysate calcium profiling (dCaP); ()
low (1.25 mmol/L) dialysate calcium (LdCa); ()
medium (1.5 mmol/L) dialysate calcium (MdCa).
The numbers above horizontal arrows are the
mean changes in cardiac indices during the first
half (0 to 2 hours) and second half (2 to 4 hours)
of a four-hour HD session. Vertical arrows in-
dicate the mean differences in cardiac indices
between the three treatment groups at the end
of HD, which are presented in the left lower
part of each graph. The corresponding mean
differences in the middle of HD were not statis-
tically significant and pertaining data are not
shown. The 95% confidence interval for the
means is given in parentheses. Unidirectional
arrows are used for simplicity, although the
order in which participants were given the dCa
treatments was random with a crossover de-
sign. *P  0.05, **P  0.01, ***P  0.001.
this is not yet proven) fewer undesirable effects on bone in the hemodynamic study (study A) also could be de-
tected in the short-term chronic study (study B). Theseturnover than the standard treatment.
In the hemodynamic study, dialysis with 1.25 and results confirmed the existing positive correlation (r be-
tween 0.67 and 0.69) between the intradialytic changes1.5 mmol/L dCa throughout the HD session caused MAP
to fall by 16.5% and 15.4% at the end of HD, respec- in iCa and arterial blood pressure previously detected
by other authors [12, 19], and further emphasized thetively, whereas iCa values remained unchanged. These
findings are in agreement with the results of previous clinical implications of this correlation in the HD setting.
In both our studies, changing the dCa concentrations ininvestigations [9–12], where MAP dropped by 9 to 21%
after lowering the dCa concentration. In the dCaP group, the middle of the HD resulted in a significant increase
in BP in the second half of HD. These data imply thata 12.6% reduction in MAP was observed in the first half
of HD when the 1.25 mmol/L dCa was used. However, a surge in iCa increase at any point during HD, by in-
creasing the dCa level to 1.75 mmol/L, can predictablyduring the second half of HD, upon switching from 1.25
to 1.75 mmol/L dCa, MAP and iCa increased by 7.8% increase BP beyond this time point. The anticipated ben-
eficial effects of this BP increase on dialysis tolerance inand 10.2% from the middle HD values, respectively. The
BP differences between the three dCa treatments found the second half of HD were found in both series, by the
Kyriazis et al: Dialysate Ca profiling during HD284
Fig. 6. Hourly intradialytic percent changes in MAP in non-responders
(A) and responders (B). See text for details. Symbols are: () dialysate
calcium profiling (dCaP); () low (1.25 mmol/L) dialysate calcium
(LdCa); () medium (1.5 mmol/L) dialysate calcium (MdCa); (*) statis-
tically significant difference between dCaP group and both LdCa and
MdCa groups. Data points represent mean values  SEM.
inducible iCa increments toward the end of HD can
counteract the negative effect of fluid removal on blood
pressure at this time period, when intradialytic hypoten-
sion occurs more frequently.
This therapeutic strategy was envisaged as a means to
protect against HD related hypotension seen with the
use of 1.25 mmol/L dCa. Interestingly, this study showedFig. 5. Hourly intradialytic percent changes in systolic blood pressure
(SBP), diastolic blood pressure (DBP) and mean arterial pressure that patients with considerable vascular instability, irre-
(MAP). Symbols are: () dialysate calcium profiling (dCaP); () low spective of sex and age, can benefit most by this tech-(1.25 mmol/L) dialysate calcium (LdCa); () medium (1.5 mmol/L)
nique, whereas it can be of little or no help in hemody-dialysate calcium (MdCa); (*) significant difference between dCaP
group and both LdCa and MdCa groups; () significant difference namically stable patients. In five out of eight patients in
between dCaP and LdCa groups. Data points represent mean values  study B, whose SBP dropped by 23% at the end of LdCaSEM (Study B, N  8).
dialysis, calcium infusion in the middle of HD confined
the SBP decrease to only 10% (P  0.05) at the end of
dCaP treatment. On the contrary, in the remaining threereduced incidence of symptomatic hypotension in the
patients, in whom an 11% reduction of SBP was observeddCaP group as compared to the LdCa and MdCa groups.
upon using 1.25 mmol/L dCa, the dCaP interventionThe observed effectiveness of dCa profiling to improve
hemodynamic instability is understandable, as long as caused SBP to fall insignificantly by 7.3% (P  0.06) at
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Table 2. Intradialytic symptoms, during 72 hemodialysis sessions, with dialysate calcium profiling (dCaP) treatment, low (1.25 mmol/L)
dialysate calcium (LdCa) treatment, and medium (1.5 mmol/L) dialysate calcium (MdCa) treatment
Treatment N (%)
P value
dCaP vs. dCaP vs. LdCa vs.
Symptom dCaP LdCa MdCa LdCa MdCa MdCa
Symptomatic hypotension 4 (5.6) 9 (12.5) 11 (15.3) 0.063 0.059 0.1
Late 1 (1.4) 7 (9.7) 8 (11.1) 0.031 0.039 0.1
Asymptomatic hypotension 1 (1.4) 4 (5.6) 4 (5.6) 0.1 0.1 0.1
Total hypotension 5 (6.9) 13 (18.1) 15 (20.8) 0.041 0.039 0.1
Late 1 (1.4) 9 (12.5) 10 (13.9) 0.008 0.012 0.1
Dialysis intolerance 5 (6.9) 7 (9.7) 7 (9.7) 0.1 0.1 0.1
Total symptoms 10 (13.9) 20 (27.8) 22 (30.6) 0.041 0.017 0.1
the end of HD. Thus, these preliminary data suggest that a better repeatability in serial measurements within the
same patient than the thermodilution method [15]. Thethe use of Ca-profiled HD may be helpful for any patient
whose SBP falls by more 20% during HD when treated reproducibility of the method assessed by George et al in
their HD patients was quite impressive [22]. The authorswith 1.25 mmol/L dCa. Given that this study was a small
sized observational study, the potential advantages of found a coefficient of variation of 5% within a single
dialysis (3 CI measurements) and 9% across means ofdCaP and the factors that can predict a positive hemody-
namic effect regarding dialysis tolerance should be ad- two intradialytic CI measurements taken three months
apart. The fact that the pre-HD CI was similar in thedressed in further larger scale studies. To facilitate the
conduction of such studies, dialysis technology must be three study groups (Table 1) confirms the reproducibility
data of the previous study. TEB is very suitable and usedprompted to incorporate pre-set Ca profiling programs
into the dialysis machines. The advent of monitoring dCa extensively to monitor systemic hemodynamics during
HD [23, 24]. In the present study, TEB enabled us tolevel on line may spread our understanding regarding the
mechanisms of HD intolerance and help readily identify identify and describe the potentially beneficial role of
dCa profiling on dialysis tolerance.intradialytic hypotension-prone individuals suitable for
Ca-profiled HD, since many observations can be taken The present study was designed to investigate whether
dCa profiling can affect the hemodynamic profile duringrepeatedly on the susceptible patients.
Acute changes of calcemia during HD affected sys- HD, and the results clearly showed its protective role
against intradialytic hypotension. Calcium fluxes duringtemic blood pressure primarily through changes in left
ventricular output rather than in peripheral vascular HD were not monitored, so we cannot infer anything about
the long-term effects of dCa modeling on bone disease;tone, and these data are consistent with those in previous
investigations [9, 14, 20]. Intradialytic alterations in iCa this question requires further investigation. However,
based on the results of our short-term study and thehave a direct effect on left ventricular performance due
to changes in ventricular contractility, independently of existing published experience, some statements can be
made regarding the possible effects on calcium metabo-changes in ventricular loading conditions and heart rate
[14]. In this context, the question of whether or not the lism by this maneuver.
First, the mean three-week pre-HD iCa value did notimpaired myocardial contractility is a limiting factor to
the dCaP was not answered by the present protocol, and differ significantly among the three dCa treatments. Tak-
ing into consideration that all patients at least six monthstherefore, it should be addressed in future crossover
studies. Given that the frequency of HD-related hemo- prior to the study had a pre-HD iCa higher than 1.38
mmol/L when treated with 1.75 mmol/L dCa, these find-dynamic instability is increased in cardiac compromised
patients, it would be of paramount importance to verify ings indicated that each of the three dCa treatments were
equally effective in preventing the HD-related hypercal-if this substantiated beneficial hemodynamic effect of-
fered by Ca-profiled HD still can enhance cardiac perfor- cemia seen with 1.75 mmol/L dCa. Therefore, although
dCaP may exert the same effects on intradialytic Camance in those patients, when challenged with adverse
hemodynamic conditions. We opted not to include pa- balance as 1.5 mmol/L dCa, the former is significantly
superior to the latter in sustaining BP during HD.tients with severely compromised left cardiac function in
our study, aiming to avoid confounding our preliminary Second, in agreement with previous investigations [3,
5, 6, 9–11], iCa during HD related directly to dCa concen-results with measurements taken in situations with im-
paired myocardial contractile reserve [21]. trations and varied with them in a time-dependent man-
ner [5, 6]. In the case of the dCaP group, during theThoracic electric bioimpedance, as a method to deter-
mine cardiac output, is highly accurate [16–18] and has first two hours iCa decreased from 1.22 to 1.17 mmol/L,
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whereas during the last two hours it increased from a the dCa concentrations for use are properly selected,
based on pre-HD iCa levels, this technique can protectmiddle HD value of 1.17 to 1.28 mmol/L at the end of
HD. Based on these findings, a lower post-HD iCa level against intradialytic and interdialytic excessive fluctua-
tions of iCa, which is a significant cause of patient mor-could have been obtained in our study with the same
pre-HD iCa level of 1.22 mmol/L, either by using a lower bidity. Whether the dCa profiling strategy has a role in
the prevention of intradialytic hypotension, as is the casedCa concentration to start dialysis (for instance, 1 mmol/L
or even less) or by switching the dCa concentrations at with Na and ultrafiltration rate profiling [28], at least in
the subset of patients with a hypercalcemic tendency,a later stage into the dialysis (for instance, at 3 instead
of 2 hours of dialysis). Therefore, it is likely that by remains to be seen.
individualizing the Ca-profiled dialysis on a patient-by-
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